Industry Insights: Healthcare
In this weekโs insights, we present three recent talking points and findings in the healthcare industry.
๐๐ผ๐น๐ผ๐ฟ๐ฒ๐ฐ๐๐ฎ๐น ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ถ๐ ๐ผ๐ป ๐๐ต๐ฒ ๐ฟ๐ถ๐๐ฒ ๐ฎ๐บ๐ผ๐ป๐ด๐๐ ๐๐ผ๐๐ป๐ด๐ฒ๐ฟ ๐ฎ๐ฑ๐๐น๐๐
Colorectal cancer (CRC) has become the leading cause of cancer-related death in adults younger than 50 years in the US. A recent analysis from JAMA pointed to delayed diagnosis, low screening uptake, and rising exposure to modifiable risk factors as key contributors to the rise. CRC screening guidelines have expanded to include younger age groups; however, their implementation remains uneven. The findings from the analysis called for improved awareness of CRC symptoms in young people and broad access to preventive strategies.
Link to JAMA article abstract: https://shorturl.at/gUXCk
๐๐๐-๐ถ๐ป๐ต๐ถ๐ฏ๐ถ๐๐ผ๐ฟ๐ ๐ฐ๐ฎ๐ป ๐ถ๐บ๐ฝ๐ฟ๐ผ๐๐ฒ ๐๐๐ฟ๐๐ถ๐๐ฎ๐น ๐ถ๐ป ๐ฝ๐๐น๐บ๐ผ๐ป๐ฎ๐ฟ๐ ๐ณ๐ถ๐ฏ๐ฟ๐ผ๐๐ถ๐
Recent evidence published in Chest suggested that angiotensin-converting enzyme (ACE) inhibitors may reduce mortality in patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic lung disease that causes irreversible scarring of the lung tissue. In the study, researchers found a consistent association between ACE-inhibitor use and improved survival, independent of antifibrotic therapy. The mechanism responsible for this improvement, however, remains unclear. The researchers emphasised that prospective studies will be needed to determine whether ACE-inhibitors could play a supportive role in IPF management.
Link to full Chest article: https://shorturl.at/cjE1r
๐๐๐ ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐๐ฒ๐ ๐ฌ๐จ๐ฉ๐๐ญ๐ญ๐ ๐ณ๐ผ๐ฟ ๐ฝ๐ฟ๐ฒ๐๐ฏ๐๐ผ๐ฝ๐ถ๐ฎ
The US Food and Drug Administration (FDA) has approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) for the treatment of presbyopia in adults. This marked the first FDA-approved dual-agent eye drop for presbyopia. YUVEZZI is designed to improve near vision while maintaining distance vision and tolerability. Presbyopia affects more than a billion people worldwide and currently has limited pharmacologic options. This approval may represent a step forward in addressing an everyday, age-related condition that has a substantial impact on quality of life.
Link to press release: https://shorturl.at/RZfh9
For more industry insights visit elion.nz/insights/
Want to get in touch? Contact us today at https://elion.nz/get-in-touch/.
